271 related articles for article (PubMed ID: 25248490)
21. Analysis of risperidone and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV.
Mandrioli R; Mercolini L; Lateana D; Boncompagni G; Raggi MA
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(2):167-73. PubMed ID: 21183412
[TBL] [Abstract][Full Text] [Related]
22. Immunoassay cross-reactivity of phenylephrine and methamphetamine.
Curtin LB; Cawley MJ
Pharmacotherapy; 2012 May; 32(5):e98-102. PubMed ID: 22499397
[TBL] [Abstract][Full Text] [Related]
23. Validation and Cross-Reactivity Data for Fentanyl Analogs With the Immunalysis Fentanyl ELISA.
Guerrieri D; Kjellqvist F; Kronstrand R; Gréen H
J Anal Toxicol; 2019 Jan; 43(1):18-24. PubMed ID: 30215771
[TBL] [Abstract][Full Text] [Related]
24. Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology.
Daniulaityte R; Carlson RR; Juhascik MP; Strayer KE; Sizemore IE
Int J Drug Policy; 2019 Sep; 71():3-9. PubMed ID: 31146200
[TBL] [Abstract][Full Text] [Related]
25. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines.
Vorce SP; Holler JM; Cawrse BM; Magluilo J
J Anal Toxicol; 2011 Apr; 35(3):183-7. PubMed ID: 21439156
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of liquid chromatography-tandem mass spectrometry targeted screening of 16 fentanyl analogs and U-47700 in hair: Application to 137 authentic samples.
Larabi IA; Martin M; Etting I; Pfau G; Edel Y; Alvarez JC
Drug Test Anal; 2020 Sep; 12(9):1298-1308. PubMed ID: 32476263
[TBL] [Abstract][Full Text] [Related]
27. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
Pettersson Bergstrand M; Helander A; Hansson T; Beck O
Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
[TBL] [Abstract][Full Text] [Related]
28. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
Darragh A; Snyder ML; Ptolemy AS; Melanson S
Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
[TBL] [Abstract][Full Text] [Related]
29. An enzyme-linked immunosorbent assay for urinary screening of fentanyl citrate abuse.
Makowski GS; Richter JJ; Moore RE; Eisma R; Ostheimer D; Onoroski M; Wu AH
Ann Clin Lab Sci; 1995; 25(2):169-78. PubMed ID: 7785965
[TBL] [Abstract][Full Text] [Related]
30. Comparison of immunoassay screening tests and LC-MS-MS for urine detection of benzodiazepines and their metabolites: results of a national proficiency test.
Bertol E; Vaiano F; Borsotti M; Quercioli M; Mari F
J Anal Toxicol; 2013; 37(9):659-64. PubMed ID: 23943436
[TBL] [Abstract][Full Text] [Related]
31. Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse.
Beck O; Rausberg L; Al-Saffar Y; Villen T; Karlsson L; Hansson T; Helander A
Drug Test Anal; 2014 May; 6(5):492-9. PubMed ID: 24665024
[TBL] [Abstract][Full Text] [Related]
32. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens.
Arntson A; Ofsa B; Lancaster D; Simon JR; McMullin M; Logan B
J Anal Toxicol; 2013 Jun; 37(5):284-90. PubMed ID: 23625703
[TBL] [Abstract][Full Text] [Related]
33. Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose.
Griswold MK; Chai PR; Krotulski AJ; Friscia M; Chapman B; Boyer EW; Logan BK; Babu KM
Clin Toxicol (Phila); 2018 Jan; 56(1):37-42. PubMed ID: 28681615
[TBL] [Abstract][Full Text] [Related]
34. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse.
Melanson SE; Snyder ML; Jarolim P; Flood JG
J Anal Toxicol; 2012 Apr; 36(3):201-6. PubMed ID: 22417836
[TBL] [Abstract][Full Text] [Related]
35. A new automated urine fentanyl immunoassay: technical performance and clinical utility for monitoring fentanyl compliance.
Snyder ML; Jarolim P; Melanson SE
Clin Chim Acta; 2011 May; 412(11-12):946-51. PubMed ID: 21281622
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: The role of LDT-based mass spectrometry testing.
Menlyadiev M; Suhandynata RT; Lund K; Kelner MJ; Fitzgerald RL
J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():105-113. PubMed ID: 37025609
[TBL] [Abstract][Full Text] [Related]
37. Rapid urine drug screens: diphenhydramine and methadone cross-reactivity.
Rogers SC; Pruitt CW; Crouch DJ; Caravati EM
Pediatr Emerg Care; 2010 Sep; 26(9):665-6. PubMed ID: 20838187
[TBL] [Abstract][Full Text] [Related]
38. Suitability of the DRI Hydrocodone/Hydromorphone Immunoassay in the Clinical Environment at a Lower Cutoff: Validation With LC-MS/MS Analysis.
Dixon RB; Dasgupta A
Ther Drug Monit; 2016 Dec; 38(6):787-790. PubMed ID: 27764026
[TBL] [Abstract][Full Text] [Related]
39. Validation of a lateral flow chromatographic immunoassay for the detection of fentanyl in drug samples.
Park JN; Sherman SG; Sigmund V; Breaud A; Martin K; Clarke WA
Drug Alcohol Depend; 2022 Nov; 240():109610. PubMed ID: 36115223
[TBL] [Abstract][Full Text] [Related]
40. Cross-reactivities and structure-reactivity relationships of six benzodiazepines to EMIT(®) immunoassay.
Bertol E; Vaiano F; Furlanetto S; Mari F
J Pharm Biomed Anal; 2013 Oct; 84():168-72. PubMed ID: 23835060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
